New Jersey-based pharmaceutical company UCB has sued to protect its patents for a Parkinson’s drug after an India-based company attempted to file an application to the U.S. Food and Drug Administration to create a generic version.

Takeaway: The lawsuit is an abbreviated new drug application, or ANDA, case, which is a highly active practice in New Jersey and elsewhere. Some claims focus on the timing of a new drug application, but this case includes allegations about access to information, and claims that the defendant company barred the plaintiff's in-house attorneys from accessing the application.